Showing results (581-590 of 735) with videos related to

Sort By:
Pageof 74
Nature Communications|September 24, 2021
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapyGuangchun Han, Guoliang Yang, Dapeng Hao, et al.
Ebiomedicine|June 11, 2026
Assessment of human immunity to A/H3N2 influenza subclade K during 2025 emergenceRuth Harvey, Ceilidh Welsh, Alexander Mp Byrne, et al.
Cell|September 17, 2019
UVB-Induced Tumor Heterogeneity Diminishes Immune Response in MelanomaYochai Wolf, Osnat Bartok, Sushant Patkar, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2017
Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysisChristian U Blank, James Larkin, Ana M Arance, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2026
CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal CancerFrancesca Jackson-Spence, James Larkin, Poulam Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2014
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutationsLisa Zimmer, Fabrice Barlesi, Maria Martinez-Garcia, et al.
The Lancet. Oncology|August 3, 2016
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trialPaolo A Ascierto, Grant A McArthur, Brigitte Dréno, et al.
The New England Journal of Medicine|June 20, 2024
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaGeorgina V Long, Axel Hauschild, Mario Santinami, et al.
Melanoma Research|September 27, 2022
Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case seriesJessica Louise Smith, Alexander M Menzies, Justine V Cohen, et al.
The Journal of Pathology|November 19, 2016
Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis modelsVictoria L Bridgeman, Peter B Vermeulen, Shane Foo, et al.
Pageof 74